Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2011.097 | Cognitive dysfunction and delayed cerebral infarction in Chinese aneurysmal subarachnoid hemorrhage patients | Prof. WONG George Kwok Chu |
| 2011.123 | Use of the Montreal Cognitive Assessment vs the Mini-Mental State Examination to screen for cognitive impairment in Chinese anaeurysmal subarachoid hemorrhage patients | Prof. WONG George Kwok Chu |
| 2020.627 | Intracranial aneurysms in ischemic stroke patients: a retrospective review |
Prof. WONG George Kwok Chu 黃國柱 |
| 2020.202 | Development and Validation of a Clinical Risk Score Model for Intracranial Aneurysm Screening in Ischemic Stroke Patients |
Prof. WONG George Kwok Chu 黃國柱 |
| 2018.291 | Assessment of the Impact of Ultra-Early Aneurysm Treatment on Outcomes in Patients with Poor Neurological Status after Intracranial Aneurysm Rupture |
Prof. WONG George Kwok Chu 黃國柱 |
| 2020.204 | Establishment and characterization of meningioma patient-derived organoids |
Prof. WONG George Kwok Chu 黃國柱 |
| 2022.666 | Mobile application development for impact assessment of patients after subarachnoid haemorrhage | Prof. WONG George Kwok Chu |
| 2008.076 | Disability in Young People and Adults One Year after Head Injury: Impact, Causes and Factors | Dr. Wong George Kwok-chu |
| 2008.073 | Computed Tomography Antiography and Venography in Place of Catheter Angiography for Acute Spontaneous Non-Hypertensive Intracerebral Haemorrhage | Dr. Wong George Kwok-chu |
| 2007.436 | Co-Operative Study on Brain Injury Depolarisations (COSBID): (Traumatic and Ischaemic Injury to the Human Brain) | Dr. Wong George Kwok-chu |
| 2010.075 | Prediction of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Haemorrhage using Transient Hyperemic Response Test and Implications on Length of Hospitalization | Prof. Wong George Kwok-chu |
| 2011.124 | Spot sign and contrast extravasation in traumatic intracranial hemorrhage for prediction of hematoma enlargement or neurological deterioration | Professor Wong George Kwok-chu |
| 2009.301 | Cerebral glucose metabolism after acute aneurysmal subarachnoid haemorrhage | Prof. Wong George Kwok-chu |
| 2023.312 | An Open-Label Phase 1b Study Evaluating the Safety, Tolerability, Immunogenicity and Antiviral Activity of Multiple Doses of CLB-3000 in Subjects with Chronic Hepatitis B | Prof. WONG Grace |
| 2024.007 | Secular trend of chronic liver diseases - a retrospective observational cohort study | Prof. WONG Grace |
| 2024.002 | A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects with Chronic HBV Infection | Prof. Wong Grace Lai Hung |
| 2021.106 | Prospective evaluation of a fast-track treatment pathway for patients with chronic hepatitis B under primary care |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2022.509 | Sodium-glucose co-transporter-2 inhibitor (SGLT2i) to prevent of liver complications in patients with chronic hepatitis B and diabetes mellitus: a double-blind, randomised, placebo-controlled trial |
Prof. WONG Grace Lai Hung 黃麗虹教授 |
| 2023.200 | A Phase 1, Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study of Orally Administered ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single-Ascending Doses (Part 1) and Multiple-Ascending Doses in Healthy Volunteers (Part 2), and Multiple Doses in Subjects with Chronic Hepatitis B (Part 3) |
Prof. WONG Grace Lai Hung Grace LH Wong |
| 2023.344 | A Phase 1/2 Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
| 2022.552 | Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1) |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2021.517 | A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects with Chronic Hepatitis B Infection |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2024.057 | A Long-Term Follow-up Study for Subjects with Chronic Hepatitis B Previously Treated with Imdusiran (AB-729) | Prof. WONG Grace Lai Hung |
| 2024.058 | A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101, an Oral PD-L1 Inhibitor, in Healthy Subjects and Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
| 2023.268 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Prof. WONG Grace Lai Hung |
| 2022.653 | A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection | Prof. WONG Grace Lai Hung |
| 2023.265 | A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB) |
Prof. WONG Grace Lai Hung Lai Hung Wong |
| 2023.273 | A PHASE I STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7565020 IN HEALTHY PARTICIPANTS AND IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION |
Prof. WONG Grace Lai Hung 35053759 |
| 2021.297 | A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Conatining VIR-2218, VIR-3434, and/or PEG-IFNa in Subjects with Chronic Hepatitis B Virus Infection |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2022.601 | Real-World Data to Assess HCV Patients Treated with SOF/VEL without RBV |
Prof Wong Grace Lai Hung 黃麗虹教授 |
| 2023.039 | A Phase 1b Multi-Center, Open-Label, Dose-Escalation, Prime and Boost Vaccination Evaluation of Two Chimpanzee Adenoviral Vectors in Adult Participants With Chronic HBV Infection Who Are Currently Receiving HBV Nucleos(t)ide Reverse Transcriptase Inhibitors | Prof. WONG Grace Lai Hung |
| 2022.676 | A Phase 2 Study Evaluating the Efficacy and Safety of VIR-3434 and/or VIR-2218 Containing Regimens in HBeAg-negative Participants with Low Viral Burden of Chronic Hepatitis B Infection (THRIVE) | Prof. WONG Grace Lai Hung |
| 2022.480 | A PHASE II, RANDOMISED, ADAPTIVE, OPEN-LABEL PLATFORM TRIAL TO EVALUATE EFFICACY AND SAFETY OF MULTIPLE COMBINATION THERAPIES IN PARTICIPANTS WITH CHRONIC HEPATITIS B |
Prof. WONG Grace Lai Hung 黃麗虹教授 |
| 2023.151 | A phase 2b, open-label study to evaluate the efficacy, safety, tolerability, immunogenicity and treatment regimens of VTP-300 combined with low-dose nivolumab in Chronic Hepatitis B Infection |
Prof. WONG Grace Lai Hung Grace LH Wong |
| 2022.678 | A Phase 2 Study Evaluating the Efficacy and Safety of VIR-3434 and/or VIR-2218 Containing Regimens in Participants with Chronic Hepatitis B Infection (STRIVE) | Prof. WONG Grace Lai Hung |
| 2023.684 | A phase II clinical study to evaluate the safety, efficacy, and pharmacokinetics of RBD1016 injection in participants with chronic hepatitis B | Prof. WONG Grace Lai Hung |
| 2022.324 | Chronic kidney disease progression in chronic hepatitis B patients on tenofovir alafenamide (TAF) versus entecavir |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2021.112 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Prof. WONG Grace Lai Hung |
| 2021.427 | A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) |
Prof. WONG Grace Lai Hung 黃麗虹教授 |
| 2009.169 | Prevalence of Advanced Fibrosis among Chronic Hepatitis C Patients in Hong Kong | Prof. WONG Grace Lai Hung |
| 2013.118 | Evaluation of clinical outcomes in patients with viral hepatitis B or C - a retrospective observational cohort study | Dr. WONG Grace Lai Hung |
| 2016.005 | REAL-C: Real-World Evidence from the Asia Liver Consortium for HCV |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2017.214 | Risk of hepatocellular carcinoma in patients with chronic hepatitis B achieved complete viral suppression – role of on-treatment hepatitis B surface/core-related antigen (HBsAg/HBcrAg) levels |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2017.419 | Prevention of recurrent ulcer bleeding in patients with idiopathic gastroduodenal ulcer: a double-blind randomised trial on misoprostol combined with lansoprazole versus lansoprazole alone (NRT_MISO Study) |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2014.690 | Secular trend of etiologies of hepatocellular carcinoma (HCC) - a retrospective observational cohort study | Dr. WONG Grace Lai Hung |
| 2015.089 | Dynamic change of LSM-HCC score and enhanced liver fibrosis (ELF) score to predict hepatocellular carcinoma (HCC) in chronic hepatitis B patients receiving antiviral treatment |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2015.121 | Secular trend of etiologies of hepatic events - a retrospective observational cohort study |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2017.421 | Secular trend of deaths - a retrospective observational cohort study |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2014.537 | Residual intrahepatic viral replication and the development of hepatocellular carcinoma in patients with chronic hepatitis B on oral nucleos(t)ide analogues: A longitudinal study with serial serum hepatitis B virus RNA measurement | Dr. WONG Grace Lai Hung |
| 2016.224 | Impact of long-term tenofovir disoproxil fumarate (TDF) treatment on the risk of HCC in patients with chronic hepatitis B related cirrhosis |
Dr. WONG Grace Lai Hung 黃麗虹 |
Page 220 of 254.